Table 3.
Characteristics of Trials Included in the Network Meta-Analysis of second-line treatments.
| Study (Author, Year [Reference]) |
Histology | Intervention (N) | Control (N) | Pertinent Characteristics |
|---|---|---|---|---|
|
KEYNOTE-061
(Shitara, 2019 [13]) |
Adenocarcinoma (79% vs. 79%) Tubular adenocarcinoma (7% vs. 10%) |
Pembrolizumab 200 mg Q3W (296) |
Paclitaxel 80 mg/m2 intravenously on days 1, 8, and 15 of 4-week cycles (296) | Median age: 62.5 vs. 60.0 Male: 68% vs. 70% Asian: 30% vs. 30% |
|
ATTRACTION-2
(Kato, 2019 [11]) |
ESCC (100%) |
Nivolumab 240 mg q2 weeks (each cycle was 6 weeks) (210) | Paclitaxel 100 mg/m2 q1 week for 6 weeks followed by 1 week off (each cycle was 7 weeks) and Docetaxel 75 mg/m2 q3 weeks (each cycle was 3 weeks) (209) | Median age: 64 vs. 67 Male: 85% vs. 89% Asian: 96% vs. 96% |
|
KEYNOTE-181
(Kojima, 2020 [15]) |
ESCC (63.1% vs. 64.6%) EAC (36.9% vs. 35.4%) |
Pembrolizumab 200 mg q3 weeks (314) | Paclitaxel 80–100 mg/m2 on days 1, 8, and 15 of each 28-day cycle, Docetaxel 75 mg/m2 on day 1 of each 21-day cycle, or irinotecan 180 mg/m2 on day 1 of each 14-day cycle (314) | Median age: 63 vs. 62 Male: 86.9% vs. 86.3 Asian: 38.5% vs. 38.9% |
|
ESCORT
(Huang, 2020 [17]) |
ESCC (100%) | Camrelizumab 200 mg on day 1 of each 2-week cycle (228) | Docetaxel (75 mg/m2, on day 1 of each 3-week cycle) or irinotecan 180 mg/m2, on day 1 of each 2-week cycle) (220) | Median age: 60 vs. 60 Male: 91% vs. 87% Asian: 100% |